Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
POVAN vs TYLOX-325
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Pyrvinium pamoate inhibits oxidative metabolism and glucose uptake in susceptible helminths, leading to energy depletion and paralysis of the worm. It also binds to DNA and inhibits RNA synthesis in the parasite.
Acetaminophen and oxycodone combination. Acetaminophen inhibits cyclooxygenase (COX) enzymes, primarily in the CNS, reducing prostaglandin synthesis. Oxycodone is a mu-opioid receptor agonist, activating descending pain pathways and altering pain perception.
Treatment of enterobiasis (pinworm infection) caused by Enterobius vermicularis
Management of moderate to severe pain requiring an opioid analgesic,Severe pain uncontrolled by non-opioid analgesics
Pyrantel pamoate: 11 mg/kg (maximum 1 g) orally once; repeat in 2 weeks for pinworm. For ascariasis, hookworm, trichostrongyliasis: 11 mg/kg (max 1 g) once daily for 3 days.
1-2 capsules (oxycodone 5-10 mg / acetaminophen 325-650 mg) orally every 4-6 hours as needed for pain; maximum 12 capsules per day.
Terminal elimination half-life is approximately 16 hours; clinically, this supports single-dose administration with slow elimination
Acetaminophen: 2-3 hours (prolonged in hepatic impairment). Oxycodone: 3-5 hours (extended-release preparation); terminal half-life 4.5-5.5 hours. Clinical context: repeated dosing may lead to accumulation; half-life prolongation in elderly, renal or hepatic disease.
Pyrvinium pamoate is minimally absorbed from the gastrointestinal tract; systemic metabolism is negligible. The small absorbed fraction is metabolized in the liver, but specific enzymes are not well defined.
Acetaminophen is primarily metabolized via conjugation (glucuronidation and sulfation) and via CYP2E1 (minor pathway forming toxic NAPQI). Oxycodone is metabolized via CYP3A4 (to noroxycodone) and CYP2D6 (to oxymorphone).
Primarily fecal (90%) as unchanged drug via bile; renal excretion is minimal (<1%)
Renal: acetaminophen metabolites (60-70% as glucuronide conjugate, 20-30% as sulfate conjugate, 5-10% as cysteine conjugate, 5% unchanged). Oxycodone: renal (primarily metabolites, <10% unchanged); biliary/fecal: minor (oxycodone metabolites).
Bound to plasma proteins (especially albumin) approximately 75–80%
Acetaminophen: 10-25% (albumin). Oxycodone: 45% (primarily albumin).
Apparent volume of distribution is 0.5–0.7 L/kg, consistent with moderate tissue distribution
Acetaminophen: 0.9-1.0 L/kg; extensive distribution. Oxycodone: 2.6-3.6 L/kg; high tissue penetration including CNS.
Oral bioavailability is low (<10%) due to poor absorption; acts topically in the GI tract
Acetaminophen: oral 85-90%. Oxycodone: oral 60-87% (variable first-pass metabolism).
No specific guidelines; caution in severe renal impairment (Cr Cl <30 m L/min) due to limited data.
e GFR 30-60 m L/min: administer at reduced frequency (e.g., every 8-12 hours); e GFR <30 m L/min: avoid use or use with extreme caution (reduce dose by 50% and monitor); hemodialysis: not recommended due to acetaminophen accumulation.
Contraindicated in acute hepatic disease or significant liver impairment (Child-Pugh class B or C); use not recommended.
Child-Pugh A (mild): no adjustment necessary; Child-Pugh B (moderate): reduce oxycodone dose by 50% and limit acetaminophen to ≤2000 mg/day; Child-Pugh C (severe): contraindicated.
Weight-based: 11 mg/kg (maximum 1 g) orally once for pinworm; repeat in 2 weeks. For other infections: 11 mg/kg once daily for 3 days.
Not approved for children <18 years; weight-based dosing: oxycodone 0.05-0.15 mg/kg/dose (max 5 mg) and acetaminophen 10-15 mg/kg/dose (max 650 mg) orally every 4-6 hours as needed; total daily acetaminophen ≤75 mg/kg/day.
No specific adjustments; use standard dosing with caution due to potential comorbidities and reduced hepatic function.
Initiate at lowest dose (e.g., 1 capsule every 6 hours); titrate cautiously; avoid in patients with renal impairment or hepatic dysfunction; monitor for opioid-induced constipation, respiratory depression, and acetaminophen hepatotoxicity; consider alternative non-opioid analgesics if feasible.
None
Addiction, abuse, and misuse; life-threatening respiratory depression; accidental ingestion; neonatal opioid withdrawal syndrome; risks from concomitant use with benzodiazepines or other CNS depressants; interaction with alcohol.
Gastrointestinal disturbances may occur; caution in patients with inflammatory bowel disease or severe hepatic impairment. May cause staining of stools and emesis. Avoid in pregnancy unless clearly needed.
Respiratory depression, opioid-induced hyperalgesia, adrenal insufficiency, severe hypotension, seizures, serotonin syndrome, hepatotoxicity, risk of overdose with acetaminophen, risks of use in patients with head injury or increased intracranial pressure.
Hypersensitivity to pyrvinium or any component of the formulation,Intestinal obstruction or acute abdominal conditions
Hypersensitivity to acetaminophen or oxycodone, significant respiratory depression, acute or severe bronchial asthma, known or suspected gastrointestinal obstruction, paralytic ileus.
No specific food interactions. The drug should be taken with food to reduce gastrointestinal upset.
Avoid alcohol. High-fat meals may delay absorption of oxycodone but do not significantly alter overall exposure. No specific food restrictions beyond alcohol.
Pyrvinium pamoate (Povan) is not recommended during pregnancy due to insufficient human data. Animal studies have not shown teratogenicity, but risk cannot be excluded. In first trimester, avoid use unless clearly needed. Second and third trimester: consider risk-benefit; no known fetal harm from limited reports.
Pregnancy Category C. Oxycodone crosses placenta. First trimester: risk of neural tube defects not established; avoid unless benefit outweighs risk. Second/third trimester: chronic use may cause neonatal opioid withdrawal syndrome (NOWS). Third trimester: high doses near term may cause neonatal respiratory depression.
Unknown if pyrvinium pamoate is excreted in human milk. M/P ratio not available. Caution advised, consider alternative treatment during breastfeeding.
Oxycodone is excreted in breast milk; M/P ratio approximately 3.4:1. American Academy of Pediatrics recommends cautious use; monitor infant for drowsiness, respiratory depression. Acetaminophen is compatible with breastfeeding. Overall, risk to infant is low with short-term maternal use.
No dose adjustment studied in pregnancy. Standard adult dose: 5 mg/kg base (max 350 mg) single dose. Use only if potential benefit justifies risk.
Increased clearance and volume of distribution during pregnancy may require dose adjustment. Pharmacokinetic changes: oxycodone clearance increases up to 1.6-fold in third trimester; acetaminophen clearance unchanged. Clinical monitoring of pain and adverse effects recommended; dose may need upward titration.
POVAN (pyrvinium pamoate) is primarily used for enterobiasis (pinworm infection). Administer as a single oral dose; repeat after 2 weeks to prevent reinfection. Tablets should be swallowed whole to avoid staining teeth. Drug may turn stools red. Avoid in patients with gastrointestinal disorders or inflammatory bowel disease. Monitor for nausea, vomiting, and cramping.
Tylox-325 contains oxycodone and acetaminophen. Avoid in patients with known hypersensitivity to opioids or acetaminophen. The maximum daily acetaminophen dose is 4 g; monitor for hepatotoxicity. Use with caution in patients with respiratory compromise, head injury, or increased intracranial pressure. Coadministration with CNS depressants (e.g., benzodiazepines) increases risk of respiratory depression. Constipation is common; prescribe stool softeners prophylactically. Discontinue gradually to avoid withdrawal.
Take the medication exactly as a single dose, and repeat after 2 weeks.,Swallow tablets whole; do not crush or chew to prevent mouth staining.,Stools may appear bright red; this is harmless.,Wash hands thoroughly after using the toilet and before eating to prevent reinfection.,Wash bedding and underwear in hot water; vacuum floors to remove eggs.,Treat all household members simultaneously to avoid spread.,Report persistent abdominal pain or diarrhea to your doctor.
Take exactly as prescribed; do not exceed 4 grams of acetaminophen per day from all sources.,Avoid alcohol while taking this medication.,May cause dizziness or drowsiness; do not drive or operate heavy machinery until you know how this medication affects you.,Do not take with other medications containing acetaminophen without consulting your doctor.,Contact your doctor if you experience signs of liver damage (yellow skin/eyes, dark urine, abdominal pain) or respiratory depression (slow/shallow breathing).,Store securely out of reach of others; this medication can be habit-forming and may be a target for misuse.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about POVAN vs TYLOX-325, answered by our medical review team.
POVAN is a Anthelmintic that works by Pyrvinium pamoate inhibits oxidative metabolism and glucose uptake in susceptible helminths, leading to energy depletion and paralysis of the worm. It also binds to DNA and inhibits RNA synthesis in the parasite.. TYLOX-325 is a Opioid analgesic combination that works by Acetaminophen and oxycodone combination. Acetaminophen inhibits cyclooxygenase (COX) enzymes, primarily in the CNS, reducing prostaglandin synthesis. Oxycodone is a mu-opioid receptor agonist, activating descending pain pathways and altering pain perception.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between POVAN and TYLOX-325 depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of POVAN is: Pyrantel pamoate: 11 mg/kg (maximum 1 g) orally once; repeat in 2 weeks for pinworm. For ascariasis, hookworm, trichostrongyliasis: 11 mg/kg (max 1 g) once daily for 3 days.. The standard adult dose of TYLOX-325 is: 1-2 capsules (oxycodone 5-10 mg / acetaminophen 325-650 mg) orally every 4-6 hours as needed for pain; maximum 12 capsules per day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between POVAN and TYLOX-325 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. POVAN is classified as Category C. Pyrvinium pamoate (Povan) is not recommended during pregnancy due to insufficient human data. Animal studies have not shown teratogenicity, but risk cannot be excluded. In first tr. TYLOX-325 is classified as Category C. Pregnancy Category C. Oxycodone crosses placenta. First trimester: risk of neural tube defects not established; avoid unless benefit outweighs risk. Second/third trimester: chronic. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.